ClinicalTrials.gg
CompletedNCT05981768Updated Oct 18, 2023

Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers

A Phase 1 interventional study of Cytisinicline in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
16th of 22
30 · median 202
Started
2023
with 1 other
Phase 1
6 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 16th largest by enrollment, is one of 2 that started in 2023, is one of 6 in phase 1, and was the 18th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

To assess the effect of food on the bioavailability of 3 mg cytisinicline following single-dose administration, and to evaluate the PK profile of 3 mg cytisinicline TID following multiple days of administration during Days 5-8.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Free written prior to any procedure required by the study.
  2. Willingness to accept and comply with all study procedures and restrictions.
  3. Male or female subject ≥ 18 years, at the date of signing the informed consent.
  4. Regular moderate combustible cigarette smokers (self-reported average of at least 10 cigarettes per day).
  5. (BMI) of 18.0 to 30.0 kg/m\^2, inclusive.
  6. Healthy subject, based on medical history, physical examination, vital signs, and clinical laboratory tests.
  7. Negative test results for anti- 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), surface antigen (HBsAg) and anti- virus antibodies (anti-HCVAb).
  8. A female subject is eligible if she also meets one of the following criteria:

    1. is of non- (underwent a permanent sterilization method [eg, hysterectomy, bilateral salpingectomy or bilateral oophorectomy], is clinically diagnosed infertile, or is in a state); or
    2. is of childbearing potential and agrees to use an accepted method from at least 4 weeks prior to admission and until at least 4 weeks after the last dose administration (Day 8).

Exclusion criteria

Exclusion Criteria:

AT SCREENING

  1. Known /allergic reaction to cytisinicline or any of the .
  2. Known severe hypersensitivity reaction to any other drug.
  3. Any medical condition (eg, gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (eg, cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety.
  4. Stroke or acute myocardial infarction within the previous 3 months.
  5. History of hyperthyroidism.
  6. History of psychosis or of a psychotic event.
  7. Estimated renal (CLCr) below the lower limit of the normal range (ie, 90-120 mL/min/1.73 m\^2 for males and 80-110 mL/min/1.73 m\^2 for females), based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average body surface area of 1.73 m\^2.
  8. (ALT) or aspartate aminotransferase (AST) above the (ULN) range.
  9. Positive result in urine drugs-of-abuse or ethanol tests at Screening.
  10. Excessive caffeine consumption, defined as ≥ 800 mg per day.
  11. Veins unsuitable for intravenous puncture on either arm (eg, veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
  12. Participation in any clinical trial within the previous 2 months.
  13. Use of any smoking cessation medications such as cytisinicline, bupropion, varenicline, nortriptyline, or any nicotine replacement therapy (NRT; eg, nicotine patch, nicotine chewing gum, or electronic cigarettes) in the previous 8 weeks.
  14. Participation in more than 2 clinical trials within the previous 12 months.
  15. Blood donation or significant blood loss (≥ 450 mL) due to any reason or had plasmapheresis within the previous 2 months.
  16. Female subjects who are lactating or pregnant by serum pregnancy test.
  17. Any other condition that the investigator considers the subject to be unsuitable for the study.

    AT ADMISSION

  18. Any recent disease or condition or treatment that, according to the investigator, would put the subject at undue risk due to study participation or occurred at a time frame in which may interfere with the pharmacokinetics of study drug.
  19. Use of any medicinal products, prescription and non-prescription (including vitamins, food supplements, herbal supplements [including St John's Wort]), in the previous 2 weeks, unless in the investigator's opinion the medication does not interfere with the pharmacokinetics of study drug or compromise subject safety.

    NOTE: The use of topical products without systemic absorption, acetaminophen (paracetamol) at doses of ≤ 2 grams/day, and hormonal are acceptable.

  20. Use of any smoking cessation medications (eg, cytisinicline, bupropion, varenicline, nortriptyline, or any NRT eg, nicotine patch, nicotine chewing gum, or electronic cigarettes) since Screening.
  21. Positive result in drugs-of-abuse or ethanol tests.
  22. If female, positive pregnancy test in urine.
  23. Any other condition that the investigator considers to render the subject unsuitable for the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1: Cytisinicline 3 mg Once Daily (QD), Fasting

    3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fasting conditions on Day 1 (Period 1) or Day 3 (Period 2). Participants will fast overnight for at least 10 hours before cytisinicline administration and will continue to fast for 4 hours after dosing.

    Drug: Cytisinicline

  • Experimental
    Part 1: Cytisinicline 3 mg QD, Fed

    3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fed conditions on Day 1 (Period 1) or Day 3 (Period 2). After an overnight fasting of at least 10 hours, participants will consume a standard high-fat-high-calorie meal within 30 minutes. Cytisinicline will be administered with 240 mL of water within 5 minutes after completion of the meal.

    Drug: Cytisinicline

  • Experimental
    Part 2: Cytisinicline 3 mg 3 Times Daily (TID)

    3 mg cytisinicline tablet administered TID each day on Day 5 to 8 (Period 3) as follows: Dose 1 will be administered in the morning between 7:00 and 9:00 AM,; Dose 2 at 5 hours (±10 minutes) after Dose 1; Dose 3 at 5 hours (±10 minutes) after Dose 2. Cytisinicline will be administered on an empty stomach (cytisinicline given at least 2 hours before food or 1 hour after food).

    Drug: Cytisinicline

Interventions

  • film-coated oral tablets containing 3 mg cytisinicline

    Also known as: Cytisine

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  2. Time of Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  3. Time Point Prior to the First Quantifiable Concentration (Tlag)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  4. Time of Last Quantifiable Observed Concentration (Tlast)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  5. Area Under Plasma Concentration-Time Curve (AUC) Over the Dosing Interval (AUC0-τ)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  6. AUC From Time of Dosing (t=0h) to the Time of the Last Quantifiable Concentration (AUC0-t)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  7. Total AUC Extrapolated to Infinity (AUC0-∞)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  8. Percentage of AUC0-∞ Due to Extrapolation From the Time of the Last Quantifiable Concentration (Tlast) to Infinity (%AUCextrap)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  9. Apparent Terminal Elimination Rate Constant (λz)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  10. Apparent Terminal Elimination Half-Life (t1/2)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  11. Apparent Clearance (CL/F)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  12. Apparent Volume of Distribution (V/F)

    Time frame: Day 1 (Period 1) and Day 3 (Period 2): pre-dose and up to 24 hours post-dose

  13. Pre-dose Plasma Concentration (Ctrough) for Dose 1, Dose 2 and Dose 3

    Time frame: Days 5 to 8 (Period 3): pre-dose

  14. Cmax for Dose 1, Dose 2 and Dose 3

    Time frame: Days 5-7 (Period 3): predose, Day 8 (Period 3): pre-dose and up to 5 hours post-dose (Doses 1 and 2), predose and up to 24 hours post-dose (Dose 3)

  15. Tmax for Dose 1, Dose 2 and Dose 3

    Time frame: Days 5-7 (Period 3): predose, Day 8 (Period 3): pre-dose and up to 5 hours post-dose (Doses 1 and 2), predose and up to 24 hours post-dose (Dose 3)

  16. AUC0-τ for Dose 1, Dose 2 and Dose 3

    τ=5 h for Dose 1 and Dose 2 and τ=24 h for Dose 3

    Time frame: Days 5-7 (Period 3): predose, Day 8 (Period 3): pre-dose and up to 5 hours post-dose (Doses 1 and 2), predose and up to 24 hours post-dose (Dose 3)

  17. Concentration Over the Dosing Interval (Cτ) for Dose 1, Dose 2 and Dose 3

    τ=5 h for Dose 1 and Dose 2 and τ=24 h for Dose 3

    Time frame: Days 5-7 (Period 3): predose, Day 8 (Period 3): pre-dose and up to 5 hours post-dose (Doses 1 and 2), predose and up to 24 hours post-dose (Dose 3)

  18. Apparent Terminal Elimination Half-Life Interval (t1/2) post Dose 3

    Time frame: Day 8 (Period 3): up to 24 hours post-dose 3

  19. Ratio of Cmax (R[Cmax])

    Accumulation of cytisinicline following TID administration will be assessed by estimating R(Cmax), where R is the ratio of the pharmacokinetic parameter following administration of Dose 1 on Day 8 vs. single-dose administration under fasting conditions during Period 1 or 2.

    Time frame: Day 1 (Period 1) or Day 3 (Period 2), Day 8 (Period 3): Dose 1 (up to 5 hours post-dose)

  20. Ratio of AUC0-τ (R[AUC0-τ])

    Accumulation of cytisinicline following TID administration will be assessed by estimating R(AUC0-τ), where R is the ratio of the pharmacokinetic parameter following administration of Dose 1 on Day 8 vs. single-dose administration under fasting conditions during Period 1 or 2.

    Time frame: Day 1 (Period 1) or Day 3 (Period 2), Day 8 (Period 3): Dose 1 (up to 5 hours post-dose)

  21. R(AUC0-τ/AUC0-∞)

    Time invariance will be assessed as R(AUC0-τ/AUC0-∞), where AUC0-τ is estimated on Day 8 Dose 1 and AUC0-∞ is estimated for the single-dose under fasting conditions during Period 1 or 2.

    Time frame: Day 1 (Period 1) or Day 3 (Period 2), Day 8 (Period 3): Dose 1 (up to 5 hours post-dose)

  22. Time to Steady State

    Time to steady state will be assessed by visual inspection of the Ctrough versus time plot.

    Time frame: Days 5 to 8 (Period 3): pre-dose

  23. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Time frame: From first dose of study drug through the End-of Study Visit (Day 28-31)

  24. Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)

    Time frame: Baseline through Day 9

  25. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs

    Time frame: Baseline through Day 9

  26. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Tests

    Time frame: Baseline through Day 9

07

Study locations

1 site
  • BlueClinical Phase I
    Porto, 4250-449, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2023, 1 month.

Of 34 phase 1 interventional studies under Smoking Cessation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 8, 2023
StartActual
Aug 8, 2023
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981768
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Aug 8, 2023
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Oct 18, 2023

Study contacts

Marlene Fonseca, MD
principal investigator · Blue Clinical

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion